Fundraising FoxPieris Pharmaceuticals
Boston, US · Founded 2013 · Nevada corporation · 4 known investors
Find your way into Pieris Pharmaceuticals
Sign up to see every warm intro you have to Pieris Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pieris Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DD
Darlene Deptula-HicksSr. Vice President & Chief Financal Officer2014–2017Darlene Deptula-Hicks is an executive officer at Pieris Pharmaceuticals with background in biotech and pharmaceutical finance, including prior CFO responsibilities and experience in capital raising, public company compliance, and M&A transactions across life sciences companies.
SS
Stephen S. YoderPresident and CEO2010–2024Stephen S. Yoder is an executive officer and director at Pieris Pharmaceuticals with expertise in biotech-pharma business development, intellectual property, and oncology and immunology drug development.
DM
Darlene M. Deptula-HicksSr. Vice President & Chief Financal Officer2014–2017Darlene M. Deptula-Hicks is Acting Chief Financial Officer of Pieris Pharmaceuticals and brings experience in biotech and pharmaceutical finance, including public and private company leadership, capital raising across equity and debt markets exceeding $350 million, and merger and acquisition transactions.
Board
Investors · 4
Ridgeback Capitallisted by Ridgeback CapitalNew York
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
Biotechnology Value FundreportedSan Francisco
How we know: funding news · press coverage · Not right? Tell us
Frazier Life SciencesreportedPalo Alto
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$102.1M disclosed across 4 rounds · 2014–2019
▶$32MraisedNov 2019 · 9 investors · PharmaceuticalsRule 506(b)
▶$32MraisedNov 2019 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen S. YoderExecutive Officer, Director
- Ahmed MousaExecutive Officer
- James GeraghtyDirector
- Michael RichmanDirector
- Ann Barbier, M.D., Ph.D.Director
- Hitto Kaufmann, Ph.D.Executive Officer
- Christopher KiritsyDirector
- Peter Kiener, D.Phil.Director
- Matthew L. Sherman, M.D.Director
- Maya R. Said, Sc.D.Director
- Tom BuresExecutive Officer
- Jean-Pierre Bizzari, M.D.Director
- Offering amount
- $32M
- Amount sold
- $32M
- Sales commissions
- $796.1K
- Placement agents
- William Blair & Company
- First sale
- Nov 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$16.5MraisedJun 2016 · 15 investors · BiotechnologyRule 506(b)
▶$16.5MraisedJun 2016 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Darlene Deptula-HicksExecutive Officer
- Steven PrelackDirector
- Chau KhuongDirector
- Michael RichmanDirector
- Stephen S. YoderExecutive Officer, Director
- Jean-Pierre BizzariDirector
- Offering amount
- $16.5M
- Amount sold
- $16.5M
- Sales commissions
- $1.1M
- Placement agents
- Trout Capital LLC, Oppenheimer & Co. Inc., Cowen and Company, LLC
- First sale
- Jun 2016
- Incorporated
- Corporation, Nevada, 2013
- Federal exemptions
- 06b
▶$13.6MraisedDec 2014 · 139 investors · PharmaceuticalsRule 506(b)
▶$13.6MraisedDec 2014 · 139 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chau KhuongDirector
- Darlene M. Deptula-HicksExecutive Officer
- Steven PrelackDirector
- Christina TakkeDirector
- Michael RichmanDirector
- Stephen S. YoderExecutive Officer, Director
- Offering amount
- $13.6M
- Amount sold
- $13.6M
- Minimum investment
- $2K
- Sales commissions
- $1M
- Placement agents
- Trout Capital LLC, Dinosaur Securities, L.L.C., American Portfolios Financial Services, Inc.
- First sale
- Dec 2014
- Incorporated
- Corporation, Nevada, 2013
- Federal exemptions
- 06b
▶$40MraisedDec 2014 · 21 investors · PharmaceuticalsRule 506(b)
▶$40MraisedDec 2014 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael RichmanDirector
- Christina TakkeDirector
- Chau KhuongDirector
- Darlene M. Deptula-HicksExecutive Officer
- Steven PrelackDirector
- Stephen S. YoderExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Dec 2014
- Incorporated
- Corporation, Nevada, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Pieris Pharmaceuticals went on to found or lead other companies.
Frequently asked questions
- Who are Pieris Pharmaceuticals's investors?
- Pieris Pharmaceuticals's investors include Ridgeback Capital, Biotechnology Value Fund, Frazier Life Sciences, OrbiMed.
- How much funding has Pieris Pharmaceuticals raised?
- Pieris Pharmaceuticals has disclosed $102.1M raised across 4 rounds.
- Where is Pieris Pharmaceuticals headquartered?
- Pieris Pharmaceuticals is headquartered in Boston, US.